Adlai Nortye Ltd ADR ANL
About Quantitative Ratings
Morningstar Quantitative Ratings for Stocks are generated using an algorithm that compares companies that are not under analyst coverage to peer companies that do receive analyst-driven ratings. Companies with quantitative ratings are not formally covered by a Morningstar analyst, but are statistically matched to analyst-rated companies, allowing our models to calculate a quantitative moat, fair value, and uncertainty rating.
News
Trading Information
- Previous Close Price
- $12.09
- Day Range
- $10.93–12.04
- 52-Week Range
- $0.88–17.25
- Bid/Ask
- $5.12 / $13.00
- Shares Outstanding
- 64.40M
- Market Cap
- $710.31M
- Volume/Avg
- 336,590 / 217,181
Key Statistics
- Price/Earnings (Normalized)
- —
- Price/Sales
- 25.96
- Dividend Yield (Trailing)
- 0.00%
- Dividend Yield (Forward)
- 0.00%
- Dividend Payment Schedule
- —
- Total Yield
- —
Company Profile
Adlai Nortye Ltd is a clinical-stage company at the forefront of discovering and developing cancer therapies. The company is building a robust pipeline of drug candidates focused on two key areas where it believes it can make a difference RAS-targeting therapies: its is tackling RAS-driven cancers with AN9025, an oral pan-RAS(ON) inhibitor, and AN4035, a CEACAM5-targeting ADC delivering a potent pan-RAS(ON) inhibitor directly to tumors; Next-generation cancer immunotherapies: its candidates, AN8025 (a tri-functional fusion protein of alphaPD-L1 x CD86 variant x LAG3 variant), a T-cell and antigen-presenting cell modulator, and AN4005 (a first-in-class oral small-molecule PD-L1 inhibitor), are designed to activate cancer immunity in novel ways.
- Sector
- Healthcare
- Industry
- Biotechnology
- Stock Style Box
- —
- Total Number of Employees
- 109
- Website
- https://www.adlainortye.com
Valuation
|
Metric
|
ANL
|
|---|---|
Price/Earnings (Normalized) | — |
Price/Book Value | 3.87 |
Price/Sales | 25.96 |
Price/Cash Flow | — |
Price/Earnings
No chart available
Financial Strength
|
Metric
|
ANL
|
|---|---|
Quick Ratio | 9.55 |
Current Ratio | 9.55 |
Interest Coverage | −17.51 |
Quick Ratio
ANL
Profitability
|
Metric
|
ANL
|
|---|---|
Return on Assets (Normalized) | −19.05% |
Return on Equity (Normalized) | −44.21% |
Return on Invested Capital (Normalized) | −20.49% |
Return on Assets
ANL
Biotechnology Industry Comparables
|
1-Day Chart
|
Name
|
Price
|
Morningstar Rating for Stocks
|
Capital Allocation
|
Economic Moat
|
Market Cap
|
|---|---|---|---|---|---|---|
| Vertex Pharmaceuticals Inc
VRTX
| LOCK|<#rc@N! | LOCK|R?<h! | $127B | |||
| Moderna Inc
MRNA
| LOCK|!>%C?? | LOCK|nc | $87B | |||
| Regeneron Pharmaceuticals Inc
REGN
| LOCK|f&FZ$< | LOCK|Hb!% | $81B | |||
| argenx SE ADR
ARGX
| LOCK|F@p#g! | LOCK|!V^ | $51B | |||
| BeOne Medicines Ltd ADR
ONC
| LOCK|mvz>nDj | LOCK|RY | $44B | |||
| Alnylam Pharmaceuticals Inc
ALNY
| LOCK|fTc#hX> | LOCK|L#$& | $31B | |||
| Royalty Pharma PLC Class A
RPRX
| LOCK|wPVhKvM | LOCK|PX!?K | $27B | |||
| Incyte Corp
INCY
| LOCK|<Z%m>k | LOCK|^$ | $23B | |||
| BioNTech SE ADR
BNTX
| LOCK|%Q#S^X | LOCK|c<@ | $22B | |||
| Jazz Pharmaceuticals PLC
JAZZ
| LOCK|&q<@r&S | LOCK|>mk | $14B |
United States